← SGLT2 inhibitors × glycemic control

TrialNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2025

Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial.

Bryony Beal et al.PubMed ↗Full text ↗Publisher ↗

  • Canagliflozinno clear effectHigher sustained insulin dose reductions of >50%, lower insulin initiation or a >25% insulin dose intensification.Nothing cleared the noise.

What the trial testedas reported · 4,401 people · 2025

Not counted

Raised sustained insulin dose reductions of >50%

+49%+15% to +91%

canagliflozin vs placebo

Bigger than 3 in 10 for glycemic control

As reported

HR 1.49, 95% CI 1.15–1.91

Not counted

Lowered insulin initiation or a >25% insulin dose intensification

−19%−29% to −7%

canagliflozin vs placebo

Bigger than 2 in 10 for glycemic control

As reported

HR 0.81, 95% CI 0.71–0.93

Who was studied, and how

4,401people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

canagliflozin
placebo

Raised sustained insulin dose reductions of >50%+49%

Lowered insulin initiation or a >25% insulin dose intensification−19%

randomised

the abstract, start to end

… with canagliflozin than placebo [HR 1.49 (95% CI 1.15-1.91)], although …

… compared with placebo {hazard ratio [HR] 0.81 [95% confidence interval (CI) …

← favours treatmentfavours comparator →
could be chance
Sustained insulin dose reductions of >50%canagliflozin vs placebo
HR 1.491.15–1.91
Insulin initiation or a >25% insulin dose intensification (in those not receiving and receiving insulin at baseline, respectively)canagliflozin vs placebo
HR 0.810.71–0.93
SGLT2 inhibitorsGlycemic control
1 / 4

2 papers cite it

2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 40036884